Cerity Partners LLC Purchases 9,741 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Cerity Partners LLC increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 18.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,890 shares of the company's stock after purchasing an additional 9,741 shares during the period. Cerity Partners LLC owned 0.20% of Medpace worth $20,659,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Westwind Capital raised its holdings in Medpace by 800.1% during the second quarter. Westwind Capital now owns 380,929 shares of the company's stock valued at $156,886,000 after acquiring an additional 338,610 shares during the period. Clearbridge Investments LLC lifted its holdings in Medpace by 55.1% in the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company's stock worth $166,343,000 after purchasing an additional 143,481 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Medpace by 38.3% in the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company's stock worth $182,692,000 after purchasing an additional 122,800 shares during the period. AQR Capital Management LLC grew its holdings in Medpace by 62.3% during the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company's stock valued at $127,941,000 after buying an additional 119,257 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Medpace by 1,028.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 116,683 shares of the company's stock worth $48,056,000 after buying an additional 106,343 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on MEDP shares. UBS Group cut shares of Medpace from a "buy" rating to a "neutral" rating and cut their target price for the company from $420.00 to $350.00 in a research note on Friday, September 27th. StockNews.com downgraded Medpace from a "buy" rating to a "hold" rating in a research report on Friday, September 27th. Truist Financial cut their price target on Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a report on Monday, October 14th. TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Finally, William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $380.56.

Medpace Stock Up 0.0 %

MEDP traded up $0.07 during trading on Monday, reaching $337.82. The company had a trading volume of 306,769 shares, compared to its average volume of 285,344. Medpace Holdings, Inc. has a 52 week low of $268.80 and a 52 week high of $459.77. The stock has a market cap of $10.50 billion, a P/E ratio of 29.96, a PEG ratio of 1.87 and a beta of 1.37. The business has a 50 day simple moving average of $340.14 and a 200-day simple moving average of $373.03.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.22 earnings per share. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.